Introduction
Biological disease-modifying antirheumatic drugs (DMARDs) were introduced for the treatment of juvenile idiopathic arthritis (JIA) in year 2000. They are highly effective, especially for patients who are refractory to conventional DMARDs (cDMARDs). The current treatment algorithm for JIA in Hong Kong was published more than a decade ago, when the use of biologics was not as common. 1 There has been a huge expansion in knowledge and approved medications since then. An update of practice based on the latest evidence is required, not only for specialists but also paediatricians and family physicians who may provide care to children with JIA.
The Hong Kong Society for Paediatric Rheumatology commissioned the JIA Work Group in 2016 to review this topic. The work group consists of nine paediatricians experienced in managing JIA. Our aims were: (1) to review the latest evidence on biological DMARDs in polyarticular course JIA (pcJIA, ie, those having arthritis affecting ≥5 joints irrespective of subtype at onset), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA); and (2) to propose an updated practice consensus for using biologics in these patients.
Methods
Articles about the use of biologics in pcJIA, ERA, and PsA published in English before July 2017 were identified by searching MEDLINE and PubMed. The keywords used for searching included JIA, pcJIA, ERA, PsA, eoJIA (extended oligoarticular arthritis), biologics, biological DMARDs, guidelines, recommendation, practice review, registries, adverse effects, malignancy, and infection. Publications considered relevant were clinical trials (randomised trials, reports on long-term extension phase of clinical trials), open-label studies, results from analysis of major registries, and recommendations from international regulatory organisations (United Kingdom: Clinical Commissioning Policy of National Health Service, National Institute for Health and Care Excellence; United States: American College of Rheumatology [ACR]; Australia: the Pharmaceutical Benefits Scheme, reimbursement programme for biologics use). Article screening, grading of the level of evidence, and propositions drafting were performed by two reviewers. The extracted evidence and draft propositions were presented to work group members at the first meeting held in July 2017. They were discussed and deliberated in a subsequent meeting held in March 2018. At the final meeting in May 2018, overwhelming consensus was reached on seven practice consensus statements.
Statement 1: Level of care
Care of children with JIA should preferably be shared jointly with paediatricians experienced in managing JIA.
With modern treatment strategies, a high level of disease control is possible. One study reported that more than 70% of patients (except rheumatoid factor positive polyarticular JIA) were able to reach a clinically inactive disease state within 2 years. 2 To achieve the best outcome, care plans and treatment targets should be carefully formulated together with patients and paediatricians experienced in managing JIA.
Statement 2: Therapeutic ladder
For pcJIA, ERA and PsA, patients with persistently active arthritis despite adequate use of one or more cDMARDs, or if patients are intolerant of them, treatment escalation to biological DMARDs should be considered.
Conventional DMARDs like methotrexate, leflunomide, and sulphasalazine are effective in treating pcJIA. [3] [4] [5] [6] The choice of cDMARDs usually depends on JIA subtype and patient tolerance. Nevertheless, some patients may not respond to or may be intolerant of cDMARDs. Switching to biologics should be considered in these cases.
Biological disease-modifying antirheumatic drugs: evidence of effectiveness

Anti-tumour necrosis factor inhibitors
Etanercept
Etanercept is a chimeric fusion protein that acts as soluble TNF receptor. It is approved for use in cases of: (1) pcJIA in children aged ≥2 years (Food and Drug Administration [FDA] and European Medicines Agency [EMA]) and (2) ERA and PsA in children aged ≥12 years (EMA). The dose is 0.4 mg/kg (max 25 mg) twice weekly or 0.8 mg/kg (max 50 mg) once weekly subcutaneously.
Etanercept was the first anti-TNF inhibitor approved for pcJIA. Its efficacy was demonstrated by a randomised withdrawal trial 7 , in which 69 patients with pcJIA aged 4 to 17 years who were refractory to methotrexate were enrolled in the open-label lead-in phase. Fifty one (74%) patients achieved an ACR 30 response at week 12. They were then randomised to receive either etanercept or placebo for 16 weeks. Etanercept was more effective in preventing arthritis flares (28% vs 81%, P=0.003). The median time to flare was significantly shorter in the placebo group (28 days vs 116 days, P<0.001). Long-term data from the extension phase confirmed the persistence of efficacy. 8 The use of etanercept in eoJIA, ERA, and PsA was studied by Horneff et al. 9 In all, 127 patients (60 patients with eoJIA aged 2-17 years, 38 patients with ERA aged 12-17 years, 29 patients with PsA aged 12-17 years) were recruited in an open-label multicentre study. All had persistently active disease despite the use of nonsteroidal anti-inflammatory drugs (NSAIDs; for ERA) and DMARDs (for eoJIA, ERA, and PsA). At week 12, 88.6% (95% confidence interval [CI]=81.6%-93.6%) had attained ACR 30 response. The proportion of response was similar across all three subtypes.
The efficacy of etanercept in ERA was further evaluated. In a phase III double-blinded study, 41 patients aged 6 to 17 years with active disease despite taking at least one NSAID and one DMARD were recruited. They received open-label etanercept for 24 weeks. An ACR 30 response was achieved in 38 (93%). These patients were then randomised to receive etanercept or placebo in the subsequent 24-week withdrawal phase. The odds for having a flare was significantly higher in placebo group (odds ratio=6, 95% CI=1.1-37, P=0.02). 10 The use of etanercept has now been extended to 2 years old. 11 The efficacy of administrating at 0.8 mg/kg weekly has been shown to be comparable to twice weekly dosing. 12 Etanercept can be used concomitantly with methotrexate or as monotherapy. 13
Adalimumab
Adalimumab is a fully humanised monoclonal anti-TNF antibody. It is approved for use in cases of: (1) pcJIA in children aged ≥2 years (FDA and EMA) and (2) ERA in children aged ≥6 years (EMA). The dose is once every other week at 10 mg for 10 to <15 kg, 20 mg for 15 to <30 kg, and 40 mg for ≥30 kg.
Adalimumab was shown to be effective in treating pcJIA by Lovell et al. 14 In total, 171 patients aged 4 to 17 years with active arthritis despite taking NSAIDs or methotrexate were enrolled in the 16- week open-label phase. In all, 94% of the adalimumab-methotrexate group and 74% of the adalimumab monotherapy group demonstrated an ACR 30 response. In the 32-week randomised withdrawal phase, the flare rate was significantly lower for those who remained on adalimumab. The results were more pronounced in patients receiving concomitant methotrexate (flare in placebo and methotrexate vs adalimumab and methotrexate: 65% vs 37%, P=0.02; flare in placebo vs adalimumab: 71% vs 43%, P=0.03). Efficacy was maintained in the longterm extension phase.
Burgos-Vargas et al 15 studied the effectiveness of adalimumab in 46 patients with ERA. These patients, aged 6 to 17 years, had active arthritis and enthesitis. They were randomised to receive either adalimumab or placebo. At week 12, the adalimumab group had a significantly greater percentage decrease in the number of active joints (-62.2% vs -11.6%, P=0.039).
The safety and effectiveness of adalimumab in children aged 2 to 4 years weighing <15 kg were also demonstrated. 16 Adalimumab can be used together with methotrexate or as monotherapy.
T cell co-stimulation inhibitor
Abatacept
Abatacept is a co-stimulation modulator that binds to the cluster of differentiation (CD) 80 or CD 86 ligands of the antigen-presenting cell and interferes with its interactions with T cells. Abatacept is indicated for pcJIA in children aged ≥6 years who are unresponsive to cDMARDs and at least one anti-TNF (EMA, FDA). The dose is 10 mg/kg (max 1g) infusion on day 1, 15, 29, and then every 28 days.
The efficacy of abatacept in pcJIA was assessed in a randomised withdrawal trial by Ruperto et al. 17 The enrolled patients were aged 6 to 17 years with active disease despite DMARDs including anti-TNF inhibitors. Systemic JIA patients without systemic manifestations were also eligible. Patients with ERA or PsA were not included. Among the 190 recruited patients, 27% had previously been exposed to anti-TNF therapy. At the end of the 4-month open-label phase, 123 (65%) demonstrated an ACR 30 response. After one patient left the study, the remaining 122 patients were randomised to receive abatacept (60 patients) or placebo (62 patients) for 6 months. The flare rate of the abatacept group was significantly lower than that of the placebo group (20% vs 53%, P=0.0003). The hazard ratio for having a flare in the abatacept group was 0.31 (95% CI=0.16-0.95). The median time to flare was 6 months for placebo and not assessable for abatacept because of an inadequate number of events (P=0.0002). Among patients who did not achieve ACR 30 at the end of the 4-month open-label phase, half achieved ACR 30 after longer exposure. By day 589 of the long-term extension phase, the proportions of patients achieving ACR 30, 50, 70, 90, and 100 were 90%, 88%, 75%, 57%, and 39%, respectively. 18 Abatacept can be used concomitantly with methotrexate or as monotherapy.
Anti-interleukin 6 inhibitor
Tocilizumab Tocilizumab is a humanised anti-interleukin 6 monoclonal antibody. It is indicated for pcJIA in child aged ≥2 years (FDA, EMA). The dose is once every 4 weeks intravenous infusion, 10 mg/kg for <30 kg, 8 mg/kg for ≥30 kg.
Tocilizumab is another non-anti-TNF option for pcJIA. In a phase 3, three-part randomised controlled study (CHERISH), 188 patients aged 2 to 17 years with active disease received openlabel tocilizumab for 16 weeks. In all, 166 (88%) achieved an ACR 30 response. A total of 163 were then randomised to receive tocilizumab (n=82) or placebo (n=81) for 24 weeks. Flares of JIA occurred significantly less often in the tocilizumab group (25.6% vs 48.1%, difference in means adjusted for stratification -0.21; 95% CI= -0.35 to -0.08; P=0.0024). Numerically more patients on concurrent methotrexate achieved ACR 70 and 90 responses. 19 Tocilizumab can be used concomitantly with methotrexate or as monotherapy. 
Systemic reviews of biologics
The short-term efficacies of biologics have been confirmed by systemic reviews. [20] [21] [22] While there have been no head-to-head trials between individual biologics, analysis with indirect comparisons has not shown obvious differences in efficacy. Longer-term data (mainly for etanercept) and reports from major registries also confirm biologics' effectiveness and safety. 23 The results of clinical trials are summarised in Table 1 .
Statement 3: Eligibility criteria for using biological disease-modifying antirheumatic drugs
The work group achieved overwhelming consensus on the following eligibility criteria. 
Eligible conditions, age, and biologics
Definition of adequate use of conventional disease-modifying antirheumatic drugs • Patients should have been treated with at least one cDMARD at adequate dose for at least 3 months unless toxicities are present. • Use of intra-articular steroid injections or a short course of bridging systemic corticosteroids are acceptable during trial use of cDMARDs. • In addition to cDMARDs, at least one anti-TNF
inhibitor should have been tried before starting abatacept. It usually takes 6 to 8 weeks before the effects of cDMARDs can be seen. "Adequate cDMARDs exposure" is often defined as at least 3 months. However, if one develops significant intolerance or toxicities during trial of cDMARDs, use of biologics should be considered earlier.
Definition of persistently active disease
• pcJIA: Five or more joints with active arthritis • ERA and PsA: three or more joints with active arthritis "Active arthritis" is defined as swelling, with or without limitation in movement. Joints with limitation in movement due to pain or tenderness are also considered as "active", especially those in which swelling is difficult to assess.
When deciding the number of joints required to define active disease, the work group adopted the commonly used inclusion criteria of the clinical trials. In view of the fact that the disease characteristics (eg, number of joints involved, clinical course, medication indicated) are somewhat different for Patients usually experience improvement within or around 3 months after commencement. The exception is abatacept, which may take a bit longer to achieve the desired therapeutic effect. 20 The definition of positive response is extrapolated from Pharmaceutical Benefits Scheme. It is easy to apply and does not require inflammatory markers like erythrocyte sedimentation rate and Creactive protein, as they are not always elevated.
Statement 5: Termination of treatment
Termination of treatment should be considered in the following situations: • Toxicities or medical conditions that contraindicate further use of biologics, including but not limited to severe injection reaction, severe infection, malignancy, demyelination, heart failure, etc • Pregnancy (temporary withdrawal may be appropriate for anti-TNF inhibitors) • Lack of 50% reduction in the number of joints with active arthritis after the 16th week (or 6th month for abatacept) • Persistent inactive disease state, defined as
Clinical Juvenile Arthritis Disease Activity Score ≤1, for at least 1 year The above termination criteria represent the common "end points" for stopping biologics, ie, the development of side-effects, conditions contra-indicated for use of biologics, or continuous remission of the index disease.
Pregnancy is no longer an absolute contraindication in adult patients with rheumatoid arthritis or ankylosing spondylitis who are receiving anti-TNF inhibitors. Temporary withdrawal, however, is necessary for some agents. There have been no recent updates from international organisations on the use of biologics in pregnant patients with JIA. This issue should be revisited during the next update.
Several definitions are used to describe treatment response and disease remission in JIA. 26 The Clinical Juvenile Arthritis Disease Activity Score is a composite measurement that evaluates three variables: active joint count, patient's/parents' global well-being score, and physician's global disease activity score (both on visual analogue scales). It has been shown to outperform other activity measurements in predicting the need of escalation to anti-TNF inhibitors. 27 For both oligoarticular arthritis and pcJIA, a score of ≤1 signifies inactive disease.
Statement 6: Malignancy and infection
• The risk of developing new-onset malignancy due to exposure to biological DMARDs is low. Careful screening and close monitoring are recommended.
• Patients on biological DMARDs should follow vaccination schedules according to local recommendations except for live attenuated vaccines. Infection screening should be performed prior to commencement. Screening should include (but not be limited to) tuberculosis, hepatitis B and C. Individual risk profiles should also be taken into consideration.
In 2008, the FDA issued a black box warning about the development of malignancy, particularly lymphoproliferative types, in 48 children after commencement of anti-TNF inhibitors between 2001 and 2008. 28 In recent years, researchers investigated the risk of malignancy by analysing data generated from major registries and medical reimbursement databases. These data suggested that TNF inhibition alone is probably not causing the apparent increase in incident malignancy. Instead, those children's background risk might have already been elevated compared with that of the general population. Nevertheless, much longer-term data on larger patient samples are needed, as both cancer and JIA are rare in children. [29] [30] [31] Data on the associations between malignancy and other non-anti-TNF biologics are still lacking. Careful screening prior to commencement and ongoing surveillance are necessary.
As for infection, biological DMARDs are generally safe. Most infections associated with the use of biologics are mild. Nevertheless, data from registries and medical insurance databases did show an increase in bacterial or serious infections associated with TNF inhibition. [32] [33] [34] Tuberculosis is a genuine concern in our locality. 35, 36 Careful screening and follow-up according to individual risk profiles is strongly encouraged. The baseline infection screening should include, but not be limited to, the following:
• Tuberculosis: Mantoux test, chest X-ray, interferon-gamma release assay • Hepatitis screening: hepatitis B surface antigen, antibody to hepatitis B core antigen, antibody to hepatitis C antigen While live attenuated vaccines should be avoided during use of biologics, patients should follow local guidelines for non-live vaccines.
Statement 7: Special consideration
• For patients with refractory disease but who do not fulfil the above criteria, biologics can be considered on a case-by-case basis.
The work group is aware that some patients who do not fulfil the above criteria might still benefit from biologics. These patients include those with persistently active and disabling multiple enthesitis or sacroiliitis despite NSAIDs and DMARDs or oligoarticular JIA with severely active arthritis and has exhausted treatment modalities including intra-articular steroid injections and multiple cDMARDs, etc. The use of biologics can be The key recommendations and treatment algorithm are summarised in Table 3 
Looking ahead: new indications after the review period
The indications for use of biological DMARDs have been expanding. For example, subcutaneous abatacept and tocilizumab are approved for pcJIA in patients aged ≥2 years in the United States. [37] [38] [39] The ACR is also preparing a new update of the 2011 and 2013 guidelines. A review of the practice should be performed regularly.
Conclusion
The use of biological DMARDs has greatly improved the management of patients with JIA. Both patients 
